• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

EDL MIC Testing Services

EDL MIC Testing Services The EUCAST Development Laboratory in Växjö, Sweden offers to determine minimum inhibitory concentrations (MICs) using broth microdilution according to the ISO standard 20776-1 (2019) to offer colleagues high quality MIC determination. The service is primarily organised to…

Get to know more

EUCAST abandons the term "intrinsic resistance" in favor of "expected resistant phenotype"

For many years EUCAST and other committees have struggled with the term “intrinsic resistance”. There is no agreed definition and since breakpoints are always “exposure dependent” it is hard to agree on a definition which will survive changes in dosing, modes of administration and a sudden…

Get to know more

Steering Committee

EUCAST Steering Committee The ESCMID-appointed Steering Committee consists of the Chair, Scientific Secretary, Clinical Data Co-ordinator, Technical Data Co-ordinator, Head of the EUCAST Development Laboratory, Educational Officer, Webmaster, Pharmacokinetic/Pharmacodynamic experts, a representative…

Get to know more

EUCAST Panel of S. pneumoniae and betalactam agents

EUCAST Panel of S. pneumoniae and betalactam agents The panel consists of 10 strains of Streptococcus pneumoniae with reference MIC values (mg/L) representing varying levels of susceptibility to beta-lactam agents, from wild type isolates to highly resistant. However, although the selection of…

Get to know more

The EUCAST subcommittee on the role of WGS in AST re-established

The EUCAST subcommittee on the role of whole genome sequencing in antimicrobial susceptibility testing has been re-established, under the leadership of Antonio Oliver (Spain). These are the findings and the conclusions of the previous subcommittee, published in 2017 (…

Get to know more

MH-F vs. MH-S for AST of fastidious organisms

The EUCAST preferred and recommended medium for AST of fastidious microorganisms is still MH-F, but MH-S can be used for most. EUCAST has now systematically compared _ MH-F and MH-S to see if the media are interchangeable. MH-F contains 5% mechanically defibrinated horse blood and beta-NAD and will…

Get to know more

Definition of S, I and R

Definitions of S, I and R EUCAST in 2019 changed the definitions of susceptibility testing categories S, I and R as shown below. Results of several consultations on the new definitions are available on the EUCAST website under “Consultations”. S - Susceptible , standard dosing regimen: A…

Get to know more

RAST Publications

RAST Publications EUCAST RAST is implemented widely. An increasing number of publications are available. Via library searches for "EUCAST" and "EUCAST RAST" we have identified an array of publications. They are presented in reverse chronological order. 2023 2022 2021 2020 Evaluation of prolonged…

Get to know more

IVDR and EUCAST

IVDR and EUCAST The IVDR ( EU regulation 2017/746 on in vitro diagnostic medical devices ) was published in April 2017 and is closely aligned to the EU regulation on medical devices. EUCAST receives many queries on how this regulation affects EUCAST recommendations and guidance. After having…

Get to know more

Antifungal Susceptibility Testing (AFST)

Subcommittee on Antifungal Susceptibility Testing (AFST) The EUCAST Subcommittee on Antifungal Susceptibility Testing (EUCAST AFST) is a standing EUCAST subcommittee which deals with all aspects of antifungal susceptibility testing, including breakpoints for antifungal agents. Steering Committee…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here